YR0006
Human IL-1B Beta Monoclonal Antibody
Size
£268.00
- SKU:
- YR0006
- Additional Names:
- IL-1|IL1-BETA|IL1B|IL1beta|IL1F2
- Application:
- ELISA, FuncS, Neutralisation
- Molecular Weight:
- 150 kDa
- Purity:
- >95%
- Storage Conditions:
- 2-8[o]C Avoid freeze/thaw cycles., -70[o]C Avoid freeze/thaw cycles.
- Supplier:
- Abclonal
- Immunogen:
- IL-1β
- Formulation:
- Purified from cell culture supernatant in an animal-free facility
- Uniprot:
- P01584
- Synonyms:
- catabolin;IL-1;IL-1 beta;IL1-BETA;IL1beta;IL1F2;interleukin 1beta;interleukin-1 beta;preinterleukin 1 beta;pro-interleukin-1-beta
- Extra Details:
- Canakinumab is a recombinant human monoclonal antibody which binds to IL-1B Beta (interleukin-1 beta). It's mode of action is based on the neutralization of IL-1B Beta signaling, resulting in suppression of inflammation in patients with disorders of autoimmune origin. In June 2009, the FDA approved canakinumab for the treatment of cryopyrin-associated periodic syndromes (CAPS), a spectrum of autoinflammatory syndromes. In September 2016, the FDA approved it's use for three additional rare and serious auto-inflammatory diseases: tumor necrosis factor receptor associated periodic syndrome (TRAPS),hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD), and familial Mediterranean fever (FMF). In June 2020, canakinumab was FDA-approved for the indication to treat active Still's disease, including adult-onset Still's disease (AOSD).
- Shipping Conditions:
- Blue Ice